基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 原料药 抗肿瘤药 替尼类抗肿瘤药 二对甲苯磺酸拉帕替尼 Lapatinib
  • Lapatinib

Lapatinib

Lapatinib
北京 更新日期:2012-05-28

Selleckchem LLC

非会员
联系人:Marketing
电话:+1-832-582-8158拨打
邮箱:marketing@selleckchemicals.com

产品详情:

中文名称:
Lapatinib
英文名称:
Lapatinib
CAS号:
388082-77-7

With the exception of ErbB-4, Lapatinib is >300-fold selective for EGFR and ErbB-2 over other kinases tested including c-Src, MEK and ERK. Treatment with Lapatinib inhibits receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner with IC50 of 0.17 and  0.08 μM against BT474 and HN5 cell lines, respectively.  The ability of Lapatinib to inhibit EGFR and ErbB-2 autophosphorylation in EGFR- and ErbB-2-overexpressing tumor cells is ∼10-fold less than its potency on the purified enzyme. Lapatinib inhibits the growth of both EGFR- and ErbB-2-overexpressing cells, whereas OSI-774 and Iressa which are EGFR selective inhibitors preferentially inhibit the growth of the EGFR-overexpressing cell lines. Lapatinib is ∼100-fold more potent on the tumor cell lines than on the normal fibroblast cells. The ErbB-2-transfected mammary epithelial cell line, HB4a c5.2, is ∼40-fold more responsive to Lapatinib treatment than the untransfected parental control line, HB4a. Transient exposure to 30 μM Lapatinib results in complete inhibition of outgrowth of the HN5 cell population after ∼2 additional weeks of culture without Lapatinib. Inhibition of outgrowth by 50% occurs at concentrations >3.3 μM. Significant inhibition of outgrowth (20%) occurs at doses as low as 0.37 μM. Another EGFR-overexpressing cell line, A-431, responds similarly to HN5. Lapatinib is similar to OSI-774 in its ability to inhibit outgrowth of the EGFR-overexpressing cell line.

HER2 Inhibitors

成立日期
注册资本
员工人数
年营业额
经营模式
主营行业

Lapatinib相关厂家报价

内容声明
拨打电话 立即询价